Recurrent Clostridioides difficile infection: Recognition, management, prevention

被引:18
|
作者
Tsigrelis, Constantine [1 ,2 ]
机构
[1] Cleveland Clin, Dept Infect Dis, G21,9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
关键词
FECAL MICROBIOTA TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINES; HEALTH-CARE EPIDEMIOLOGY; INTESTINAL MICROBIOME; DISEASES SOCIETY; VANCOMYCIN; BEZLOTOXUMAB; UPDATE; ADULTS; FIDAXOMICIN;
D O I
10.3949/ccjm.87gr.20001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clostridioides difficile infection (CDI) is the most common cause of diarrhea in hospitalized patients and results in substantial morbidity, mortality, and costs. Its clinical management, primarily with antibiotics, is often complicated by recurrent episodes. These recurrent CDI episodes are thought to be caused by antibiotic disruption of colonic microbiota and usually occur within 4 weeks of completing antibiotic therapy. The risk of recurrent CDI increases after the first episode, creating a need for management strategies to diagnose, treat, and prevent these complications.
引用
收藏
页码:347 / 359
页数:13
相关论文
共 50 条
  • [41] Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies
    Parul Berry
    Sahil Khanna
    BioDrugs, 2023, 37 : 757 - 773
  • [42] Diagnostic and therapeutic management of Clostridioides difficile infection
    Zunigaa, Miguel angel Lopez
    Cabellob, Antonio Sanchez
    Ruza, Miguel angel Lopez
    MEDICINA CLINICA, 2025, 164 (03): : 136 - 142
  • [43] Melatonin as an Antimicrobial Adjuvant and Anti-Inflammatory for the Management of Recurrent Clostridioides difficile Infection
    Sutton, S. Scott
    Magagnoli, Joseph
    Cummings, Tammy H.
    Hardin, James W.
    ANTIBIOTICS-BASEL, 2022, 11 (11):
  • [44] Practical Use of Fecal Microbiota Spores, Live BRPK for the Prevention of Recurrent Clostridioides difficile Infection
    Allegretti, Jessica R.
    Khanna, Sahil
    Feuerstadt, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12): : 2106 - 2108
  • [45] Real World Experience of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Mayo Clinic Experience
    Sehgal, Kanika
    Tariq, Raseen
    Pardi, Darrell S.
    Khanna, Sahil
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S141 - S141
  • [46] Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies
    Berry, Parul
    Khanna, Sahil
    BIODRUGS, 2023, 37 (06) : 757 - 773
  • [47] Live Biotherapeutic Products for the Prevention of Recurrent Clostridioides difficile Infection (vol 28, 10600280241239685, 2024)
    Pettit, N. N.
    Shaeer, K. M.
    Chahine, E. B.
    ANNALS OF PHARMACOTHERAPY, 2025,
  • [48] Primary prevention of Clostridioides difficile infection with combination probiotics
    Nagamine, T.
    JOURNAL OF HOSPITAL INFECTION, 2020, 104 (01) : 80 - 81
  • [49] Clostridioides difficile Infection in Children: The Role of Infection Prevention and Antimicrobial Stewardship
    Savage, Timothy J.
    Sandora, Thomas J.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 : S64 - S68
  • [50] Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection
    Normington, Charmaine
    Moura, Ines B.
    Bryant, Jessica A.
    Ewin, Duncan J.
    Clark, Emma, V
    Kettle, Morgan J.
    Harris, Hannah C.
    Spittal, William
    Davis, Georgina
    Henn, Matthew R.
    Ford, Christopher B.
    Wilcox, Mark H.
    Buckley, Anthony M.
    NPJ BIOFILMS AND MICROBIOMES, 2021, 7 (01)